Short daily versus conventional hemodialysis for hypertensive patients: a randomized cross-over study by Zimmerman, Deborah L. et al.
  
 
 
 
Zimmerman, Deborah L., Ruzicka, Marcel, Hebert, Paul, Fergusson, Dean, 
Touyz, Rhian M., and Burns, Kevin D. (2014) Short daily versus conventional 
hemodialysis for hypertensive patients: a randomized cross-over study. PLoS 
ONE, 9 (5). e97135. ISSN 1932-6203 
 
 
 
Copyright © 2014 The Authors 
 
 
 
http://eprints.gla.ac.uk/94854 
 
 
 
Deposited on:  04 July 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Short Daily versus Conventional Hemodialysis for
Hypertensive Patients: A Randomized Cross-Over Study
Deborah L. Zimmerman1*, Marcel Ruzicka1, Paul Hebert2, Dean Fergusson3, Rhian M. Touyz4,
Kevin D. Burns5
1Associate Professor of Medicine, Division of Nephrology, Ottawa Hospital, Kidney Research Centre of the Ottawa Hospital Research Institute, University of Ottawa,
Ottawa, Ontario, Canada, 2 Professor of Medicine, Surgery, Anesthesia and Epidemiology, University of Ottawa; Senior Scientist, Clinical Epidemiology, Ottawa Hospital
Research Institute, Ottawa, Ontario, Canada, 3Associate Professor, Departments of Medicine, Surgery, Epidemiology and Community Medicine, Senior Scientist and
Director, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, 4 Institute of Cardiovascular and Medical Sciences, BHF Glasgow
Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom, 5 Professor of Medicine, Division of Nephrology, Senior Scientist, Kidney Research
Centre of the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
Abstract
Background: Treatment of end stage renal disease patients with short daily hemodialysis has been associated with an
improvement in blood pressure. It is unclear from these studies if anti-hypertensive management had been optimized prior
to starting short daily hemodialysis. Also, the potential mechanism(s) of blood pressure improvement remain to be fully
elucidated.
Study Design, Setting and Participants: We undertook a randomized cross-over trial in adult hypertensive patients with
ESRD treated with conventional hemodialysis to determine: 1) if short-daily hemodialysis is associated with a reduction in
systolic blood pressure after a 3-month blood pressure optimization period and; 2) the potential mechanism(s) of blood
pressure reduction. Blood pressure was measured using Canadian Hypertension Education Program guidelines. Extracellular
fluid volume (ECFV) was assessed with bioimpedance. Serum catecholamines were used to assess the sympathetic nervous
system. Interleukin-6 (IL-6) and thiobarbituric acid reactive substances (T-BARS) were used as markers of inflammation and
oxidative stress respectively.
Results: After a 3-month run-in phase in which systolic blood pressure improved, there was no significant difference in pre-
dialysis systolic pressure between short-daily and conventional hemodialysis (p = 0.39). However, similar blood pressures
were achieved on fewer anti-hypertensive medications with short daily hemodialysis compared to conventional
hemodialysis (p = 0.01). Short daily hemodialysis, compared to conventional hemodialysis, was not associated with a
difference in dry weight or ECFV (p = 0.77). Sympathetic nervous system activity as assessed by plasma epinephrine (p = 1.0)
and norepinephrine (p = 0.52) was also not different. Markers of inflammation (p = 0.42) and oxidative stress (p = 0.83) were
also similar between the two treatment arms.
Conclusions: Patients treated with short daily, compared to conventional hemodialysis, have similar blood pressure control
on fewer anti-hypertensive medications. The mechanism(s) by which short daily hemodialysis allows for decreased anti-
hypertensive medication use remains unclear but effects on sodium balance and changes in peripheral vascular resistance
require further study.
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Introduction
More than 50% of the patients with end stage renal disease
(ESRD) die from cardiovascular disease, a risk 10–20 times greater
than the general population [1,2]. Of the potentially modifiable
cardiovascular risk factors, greater than 80% of patients with
ESRD have hypertension; 70% of whom are poorly controlled
using conventional therapy [3]. An expanded extracellular fluid
volume (ECFV) and an increase in peripheral vascular resistance
(PVR) due to hemodynamic/trophic effects of increased sympa-
thetic nerve activity and inflammation are frequently quoted
mechanisms contributing to hypertension in ESRD [4]. Common
to these processes is increased bioavailability of reactive oxygen
species [5].
The intermittent nature of conventional hemodialysis treat-
ments (4 hours, 3 days/week) results in the majority of patients
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having a fluctuating ECFV that likely contributes to the activation
of neurohormonal pathways [6]. However, daily hemodialysis
therapy including short daily (2 hours, 6 days/week) and nocturnal
(6–8 hours, 5–6 days/week) improves or even normalizes blood
pressure [6–12]. Short daily hemodialysis reportedly improves
blood pressure secondary to a reduction in ECFV [6,9] whereas
nocturnal hemodialysis appears to be associated with a reduction
in PVR [9–11]. This suggests that different mechanisms of blood
pressure reduction may vary in different patient groups. In a study
by Katzarski et al, patients who were normotensive and dialyzed
for 7–8 hours, 3 days/week were compared to normotensive and
hypertensive patients whose treatment time was 3–5 hours [13].
There was no overall difference in the ECFV and inferior vena
cava diameter between the two normotensive groups, which were
lower than the hypertensive patients. However, 24% of the
patients treated with long dialysis appeared to have an expanded
ECFV such that the authors hypothesized that normotension in
these patients might be explained by the removal of a vasoactive
hormone. Their results are supported by a small randomized
controlled trial of blood pressure control in 21 ESRD patients in
which 7 patients had their dialysis time increased by 2 hours, 6
patients had their dialysis time increased by 2 hours and dry
weight reduced, and 8 patients only had their dry weight reduced
[14]. Despite a decrease in dry weight (and presumably ECFV) in
only 2 of the groups, systolic blood pressure and use of anti-
hypertensive medication use was reduced in all 3 groups.
In the majority of reported studies it is unclear if the patient’s
antihypertensive management, including achievement of the
appropriate dry weight, had been optimized prior to the
introduction of more intensive hemodialysis. A limited number
of investigations have been undertaken to determine the mecha-
nisms of blood pressure reduction. For this reason, we undertook a
randomized cross-over trial in patients with ESRD treated with
hemodialysis. Our primary objective was to determine if short-
daily hemodialysis, compared to conventional hemodialysis, is
associated with a reduction in systolic blood pressure pre-dialysis
after an optimization period. Our secondary objective was to
determine the potential mechanism(s) of blood pressure reduction
by assessing extracellular fluid volume and the sympathetic
nervous system. The potential role of inflammation and oxidative
stress were added to the study design because of the increasing
evidence suggesting that these mediators may have an etiologic
role in hypertension [5,15].
Methods
Study Overview
We undertook a 9-month randomized, crossover trial of adult
prevalent hypertensive ESRD patients. Paperwork for the trial was
submitted to the Ottawa Hospital Research Institute in June 2007
for registration at clinicaltrials.gov as per protocol at the time but
due to administrative delays was not released until September 24,
2008 (NCT00759967). The protocol for this trial and supporting
CONSORT checklist is available; see Checklist S1 and Protocol
S1. The Ottawa Hospital Research Ethics Board approved the
study and all amendments. The study was conducted according to
the Declaration of Helsinki.
Run-in Phase
Inclusion criteria included: 1) on hemodialysis for .3 months,
2) any patient on 1 or 2 antihypertensive medications with a pre-
dialysis systolic blood pressure of .140 on average over 1 month,
3) any patient on 3 or more antihypertensive medications
regardless of pre-dialysis systolic pressure, 4) able to make the
time commitment to daily therapy, and 5) able to give informed
consent. Patients were excluded if they were expected to switch
treatment modality or die within one year or have known dilated
cardiomyopathy with an ejection fraction ,0.3. Eligible patients
provided written informed consent to the study coordinator and
then underwent a 3-month run-in phase. All patients were
dialyzed with a Fresenius K machine, Optiflux 160 dialyzer,
blood pump speed 300–400 mls/min and a dialysate flow of
500 mls/minute. A protocolized blood pressure algorithm was
followed to optimize blood pressure control (Figure 1). Briefly, all
patients met with the renal dietician. The dietary sodium (,2
grams per day) and fluid restrictions (1L per day) as per unit policy
were re-enforced. The dialysate sodium was reduced to
138 mmol/L from 140 mmol/L, the latter being the standard
sodium concentration in our Ottawa Hospital hemodialysis units.
At each hemodialysis treatment, a pre and post hemodialysis blood
pressure was measured using techniques recommended by the
Canadian Hypertension Education program. Changes were made
to dry weight and/or antihypertensive medications every 2 weeks
by the principal investigator if the 2-week average pre-dialysis
systolic blood pressure was greater than 140 mmHg. Forty-four
hour ambulatory blood pressure was also measured in the last
week of the run-in phase. The number, type and strength of
antihypertensive medications were recorded at study entry and at
the end of each month. Intensity of anti-hypertensive medication
use was estimated as multiples of the smallest available dose for
that particular medication (eg. amlodipine - smallest available dose
5 mg= 1: 10 mg=2, 2.5 mg= 0.5). Standard of care monthly
laboratory investigations (complete blood count, electrolytes,
calcium, phosphate, albumin, creatinine and pre/post hemodial-
ysis urea were collected at baseline and the last month of the run-
in phase on a Wednesday or Thursday pre-dialysis.
Randomization
After the 3 month run-in phase, patients were randomized using
a computer generated randomization sequence. Each patient
completed 3 months of conventional 3 times per week hemodi-
alysis or 6 times per week short daily hemodialysis and then
crossed-over to the other treatment arm (Fig. 2). The only
differences in the short daily dialysis prescription was to increase
the frequency from 3 days to 6 days, decrease the hemodialysis
session time by 50% and decrease the dialysate bicarbonate
concentration to 32 mmol/L from 36 mmol/L to avoid metabolic
alkalosis [16]. The assessment of blood pressure with adjustments
to weight and anti-hypertensive medications was the same as for
the run-in phase. Standard monthly laboratory investigations were
also the same except during short daily hemodialysis, blood was
collected on Monday (after a day off).
Assessment of Extracellular Fluid Volume
Post treatment extracellular fluid volume was measured with the
Xitron Hydra (Xitron Technologies, San Diego, CA) using
standard techniques. The Hydra is a multifrequency bioimpe-
dance analyzer that allows for differentiation of ECFV and
intracellular fluid volume by detecting differences in the conduc-
tive properties of cells by measuring resistance (impedance) to
electrical current. The technique is reliable in tracking sequential
changes in ECFV with a reported coefficient of variation and
intra-observer error of 2.5% [13,17]. All measurements were taken
20 minutes after completion of the hemodialysis treatment, by
placing 4 electrodes on the wrist and ankle on the non-fistula side.
Yearly calibration of the equipment was performed by the Ottawa
Hospital technical department.
Short Daily Hemodialysis For Hypertensive Patients
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Measurement of Plasma Catecholamines
Blood samples were taken post dialysis with the patient in a
quiet dark room prior to the removal of the hemodialysis needles.
The plasma samples were prepared immediately and stored at 2
80C and analyzed within 6 months by high performance liquid
chromatography at a commercial laboratory.
Markers of Inflammation and Oxidative Stress
Plasma interleukin-6 (IL-6) and plasma thiobarbituric acid
reactive substances (T-BARS) were used as markers of inflamma-
tion and oxidative stress respectively. Plasma was prepared from
blood collected in EDTA vacutainer tubes pre-dialysis and stored
at280uC. Plasma levels of IL-6 were measured using a solid-phase
sandwich ELISA kit from Biosource International according to
manufacturer’s instructions. Plasma TBARS levels were measured
colorimetrically and values were expressed in nmol/ml mal-
ondialdehyde (MDA) equivalents as we previously reported
[18,19].
Analysis
Based on our previous experience with daily hemofiltration, we
calculated that 20 patients would be required to detect a difference
of 11 mmHg in systolic blood pressure assuming a standard
deviation of 11, a two-sided alpha= 0.05, and a power of 80%
[20].
Results are expressed as means and standard deviations or
median and interquartile range depending on normality assump-
Figure 1. Protocolized Blood Pressure Management Algorithm.
doi:10.1371/journal.pone.0097135.g001
Figure 2. Flow Diagram.
doi:10.1371/journal.pone.0097135.g002
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tions for continuous data and frequency for categorical data as
appropriate. The primary analysis was intention to treat paired t-
test of the comparison of the mean pre-dialysis systolic blood
pressure values from the last month on conventional hemodialysis
and the last month of short daily hemodialysis (last value carried
forward for missing blood pressure data). As described by Zoccali
et al, this gives an assessment of the pressure load as experienced
by the left ventricle [21]. To assess order effect (or period effect) a
GEE model with SBP as outcome and treatment and period as
predictors, accounting for patient effect in repeated measures was
performed.
A paired t-test was also used for weight, ECFV, total
ultrafiltration and ultrafiltration rate. Due to the non-normal
distribution of the hypertension medication intensity score, serum
catecholamines, IL-6 and TBARs, these were compared using the
Wilcoxin sign rank test. Linear regression analysis was undertaken
to explore the predictors of the intensity of anti-hypertensive
medication use after conventional and daily hemodialysis (post-
hoc).
Results
Twenty-two patients consented to participate in the study; 3
patients withdrew prior to randomization, 2 patients did not
complete the short daily hemodialysis (Figure 3). Therefore data
from 19 patients were included in the systolic blood pressure
analysis. Patient demographics are depicted in Table 1. The
average age of the participating patients was 53 years, 11 patients
(58%) had a history of diabetes mellitus and the majority of
patients were male.
There was a statistically significant decrease in systolic blood
pressure from study entry to the end of the run in phase (151 vs
138 mmHg; p= 0.004) without an overall change in dry weight
(77.4 vs 77.1 kgs; p = 0.63) or intensity of antihypertensive
medications (5.46 vs 5.16; p = 0.57). Although we did not
demonstrate a reduction in average post dialysis body weight at
the end of the run-in phase compared to baseline, there was
tremendous variability with the weights of some participants being
decreased (maximum 8.7 kgs) and the weights of other participants
being increased (maximum 5.4 kgs). Similar changes were seen in
the anti-hypertensive medication use from baseline to the end of
the run-in phase with some patients requiring increased medica-
tion while other patients had decreased medication. Overall, there
was a decline in the amount of ultrafiltration per treatment from
the first month of the run-in phase to the last month of the run-in
phase (2.5L vs 2.3L; p = 0.007).
Of the standard biochemical tests throughout the study, serum
sodium was 138 mmol/L at baseline and 137 mmol/L at the end
of the run-in phase. This change was maintained throughout the
study. Serum phosphate declined from 1.86 mmol/L at baseline to
1.61 mmol/L at the end of the run-in phase (p = 0.04). During
conventional hemodialysis and short daily hemodialysis after
randomization, serum phosphate was 1.82 mmol/L and
1.58 mmol/L respectively (p = 0.25). Weekly Kt/V was similar
at the end of the run in phase and 3 months of conventional HD
(5.4) but increased (6.6) during short daily HD. No changes were
observed in serum potassium, calcium, bicarbonate or albumin
throughout the study.
Changes in the antihypertensive medication classes are shown in
Table 2 at baseline, after the run-in, short daily and conventional
hemodialysis phases. After 3 months of short daily, compared to 3
months of conventional hemodialysis, systolic and diastolic blood
pressures were not statistically different (p = 0.39, p = 0.56
respectively; Table 3) and there was no period effect (p = 0.40,
figure 4). These results are supported by the 44-hour ABPM.
However, these similar blood pressures were achieved on a lower
intensity of hypertension medication use in the short daily
hemodialysis phase compared to conventional hemodialysis phase
Figure 3. Trial Flow.
doi:10.1371/journal.pone.0097135.g003
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(p = 0.01, Table 4). There were no significant differences in dry
weight, ECFV, plasma epinephrine or nor-epinephrine levels
between conventional hemodialysis and short daily hemodialysis
(Table 4). There was no difference between IL-6 and TBARS by
treatment modality. Plasma catecholamines, ECFV and serum
phosphate were not significantly associated with antihypertensive
medication intensity score on conventional (p = 0.42, 0.88, 0.09
respectively) or short daily hemodialysis (p = 0.24, 0.22, 0.68
respectively).
Serious adverse events were rare during the trial. One patient
was hospitalized during the study during the short daily
hemodialysis phase with volume overload.
Discussion
Short daily hemodialysis achieves a similar degree of systolic
blood pressure control compared to conventional 3 times per week
hemodialysis after a blood pressure optimization phase. However,
this control is associated with a decreased requirement for
antihypertensive medications. Our results highlight the impor-
tance of a run-in phase using a protocolized blood pressure
algorithm when treatment modalities cannot be blinded.
The decline in blood pressure at the end of the 3 month run-in
phase, compared to baseline, was likely multifactorial. Although
we did not demonstrate a reduction in average post dialysis weight,
there was tremendous variability with some participant’s weight
being decreased and other participant’s weight being increased.
Similar changes were seen in the anti-hypertensive medication use.
A reduction in dialysate sodium has been associated with a
reduction in blood pressure in hypertensive patients without a
change in pre-dialysis serum sodium concentration in some
[22,23] but not all studies [24]. Post dialysis increases in serum
sodium have been demonstrated for patients treated with
Table 1. Baseline Patient Characteristics.
Patient Characteristics
Age – Years (SD) 53 (13)
Gender (M:F) 13:6
Dialysis Vintage – Day (SD) 1368 (1670)
Charlson Comorbidity Score (SD) 6 (2)
Etiology of ESRD DM (7), GN (6), HTN (2), Multiple Myeloma (1), Amyloid (1), Other (2)
History of Diabetes Mellitus (Y/N) 11/8
Access Type (AVF/AVG/CVC) 11/2/6
Dry Weight (kgs) 77.4 (14.3)
Baseline BP (SD) 151 (12)/79 (9)
HTN Medication Intensity Score 5.46 (2.94)
SD – standard deviation, M – Male, F – Female, HTN – hypertension, ESRD – end stage renal disease,
DM – diabetes mellitus, GN – glomerulonephritis (includes IgA, Goodpasture’s, Immunofibrillary), Y/N – yes/no,
AVF – arteriovenous fistula, AVG – arteriovenous graft, CVC – central venous catheter, kgs – kilograms.
doi:10.1371/journal.pone.0097135.t001
Figure 4. Graph of Period Effects.
doi:10.1371/journal.pone.0097135.g004
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conventional hemodialysis with dialysate sodium that is higher
than the patient’s serum sodium with a potential increase in thirst
(occurs in 43% when dialysate sodium is 140 mmol/L, 20% when
dialysate sodium is 138 mmol/L, [25]). It is unclear if the dietary
instruction or the decrease in dialysate sodium in our study caused
the small but statistically significant decrease in the total amount of
ultrafiltration from the first month of the run in phase to the last
month of the run in phase.
The mechanism for the decrease in antihypertensive require-
ments on short daily hemodialysis, compared to conventional
hemodialysis, is unclear. A reduction in ECFV has been
demonstrated in some [6,9] but not all [7] studies as a mechanism
contributing to the blood pressure lowering effect associated with
short daily dialysis. Our study does not support this association for
the population. There are a number of potential reasons for the
differences in our results compared to other studies. To our
knowledge a protocolized blood pressure management algorithm
aimed at achieving an optimal dry weight prior to starting short
daily hemodialysis has not been followed previously. Even during
conventional hemodialysis ‘probing dry weight’ as was done in the
DRIP trial was associated with approximately 7/3 mmHg decline
in systolic and diastolic blood pressure respectively [26]. Also,
given the inability to blind these modality studies, the possibility of
differential patient management is possible.
The activity of the sympathetic nervous system was found to be
important in a study that included 11 patients treated with short
daily hemodialysis [6]. The investigators demonstrated a reduction
in ultrafiltration volumes per session almost identical to those
reported in our study. They hypothesized that large volume
fluctuations could result in greater sympathetic nervous system
stimulation. Greater amounts of ultrafiltration may also lead to
increased post dialysis serum sodium which may stimulate the
sympathetic nervous system [27]. We were unable demonstrate a
difference in serum catecholamines with short daily compared to
conventional hemodialysis but this does not rule out increase
central sympathetic outflow.
In that last decade there has been an emerging evidence to
support importance of oxidative stress in the development of
hypertension [28,29]. Hydrogen peroxide production (H2O2) was
higher in granulocytes of patients with CKD treated with
hemodialysis compared to controls [30]. The magnitude of ROS
production by granulocytes and monocytes in that study
population was significantly related to the plasma concentration
of the lipid peroxidation product, malondialdehyde (MDA), which
is commonly used as an indirect marker of oxidative stress [30].
H2O2 levels increased after hemodialysis with a cellulose acetate
dialyzer highlighting the potential deleterious effects associated
with the dialysis treatment itself [30]. We were unable to show a
difference in serum T-BARs (measure of MDA) with short daily
Table 2. Changes in Classes of Anti-Hypertensive Medications during the Trial.
Baseline Run-In CHD DHD
Ace-I 10 9 10 8
ARB 8 5 4 3
b-blocker 11 9 6 6
DHCCB 14 13 11 8
a-blocker 5 2 2 1
Central sympatholytic 1 1 1 1
Diuretic 3 4 3 4
Arterial Vasodilator 2 2 2 2
Ace-I – Angiotensin Converting Enzyme Inhibitor, ARB – angiotensin receptor blocker,
DHCCB – dihydropyridine calcium channel blocker.
doi:10.1371/journal.pone.0097135.t002
Table 3. Results of the Intervention Phases; Normally Distributed Data.
3-Months Conventional HD 3-Months Daily HD Paired-Difference p-value
Negative N(%) Positive N(%)
SBP pre-HD (mmHg; SD) 142(17) 139(14) 11(58) 8(42) 0.39
DBP pre-HD (mmHg; SD) 79(9) 80(9) 10(53) 9(47) 0.56
SBP post-HD (mmHg; SD) 127(19) 125(14) 8(42) 11(58) 0.40
DBP post-HD (mmHg; SD) 75(11) 76(8) 13(68) 6(32) 0.40
Dry Weight (kgs; SD) 77(14.4) 76.8(15.1) 9(47) 10(53) 0.70
Ultrafiltration/treatment (L; SD) 2.4(0.8) 1.3(0.6) 0(0) 19(100) ,0.001
Ultrafiltration rate (L/hr; SD) 0.60(0.20) 0.65(0.29) 12(63) 7(37) 0.17
ECFV (L; SD) 15.4(2.8) 15.2(3.2) *11(65) 6(35) 0.77
SBP – systolic blood pressure, HD – hemodialysis, SD – standard deviation, DBP – diastolic blood pressure,
kgs – kilograms, L – liter, hr - hour;
*last value not carried forward for the 2 patients who withdrew.
doi:10.1371/journal.pone.0097135.t003
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compared to conventional hemodialysis. Interestingly, phosphate
has been shown to stimulate endothelial cell apoptosis which was
characterized by increased oxidative stress [31]. It is unclear if the
effects of an increase in dialysis frequency and exposure to dialysis
tubing and membranes is counterbalanced by the improvements
in serum phosphate that have been reported with short daily
dialysis.
A generalized increase in inflammatory markers including IL-6
may occur via a number of mechanisms including volume
overload and oxidative stress. We were unable to show a difference
in IL-6 or albumin with short daily compared to conventional
hemodialysis. In a prospective cohort study of 26 patients treated
with short daily HD in-centre, Ayus et al reported significant
improvements in hs-CRP values after 12 months [32]. In a cross-
sectional study by Jefferies et al, lower CRP values were only seen
for patients who were doing more frequent dialysis at home
compared to those patients who were treated in-centre [33]. Post
dialysis sodium, ultrafiltration volumes and ultrafiltration rates
were much lower for the patients being treated at home compared
to the patients being treated in-centre suggesting that post-dialysis
increases in serum sodium and/or interdialytic ECFV expansion
may explain these differences. They were unable to demonstrate
lower IL-6 levels between patients undergoing conventional and
short daily dialysis in-centre who had similar post dialysis serum
sodium levels and ultrafiltration rates. The impact of more
frequent dialysis on markers of oxidative stress and inflammation
requires further study.
Our study has a number of limitations including the inability to
blind the patients and investigators to the treatment group. We did
not measure residual renal function and therefore could not assess
the importance of this variable. However, the dialysis vintage of
the patients suggests that many of them may have been anuric.
Lastly, we did not measure ECFV at baseline and again at the end
of the run-in phase; we are therefore unable to comment on the
role changes in ECFV in the blood pressure improvement that was
seen in the BP optimization phase. Strengths of our study over
others that have been published to date include the run-in phase
and use of standardized blood pressure algorithm.
In summary after a 3-month run-in phase in which blood
pressure was optimized by decreasing dialysate sodium, adjusting
dry weight and anti-hypertensive medications,
patients treated with short daily HD compared to conventional
HD require fewer anti-hypertensive medications to achieve the
same blood pressure. This effect on blood pressure control was not
related to a reduction in ECFV, sympathetic nervous system
activity, oxidative stress or inflammation. The mechanism(s) by
which short daily HD allows for decreased use of anti-hypertensive
medication remains unclear but may be related to effects on
sodium balance and changes in peripheral vascular resistance that
require further study.
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